SUBSCRIBE
SUBSCRIBE

Phase 1

Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
AstraZeneca PLC Continues Its Immuno-Oncology Roll, Durvalumab Gets Breathrough Designation for Bladder Cancer
February 17, 2016
 · 
2 min read
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Drug Development
Armed with $50 Million from Google, Celgene and More, ARMO BioSciences Eyes Next-Gen Cancer Drug Combos
February 10, 2016
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
AstraZeneca PLC’s Immunotherapy Lung Cancer Combo Treatment Sees Breakthrough in Early Stage Trial
February 8, 2016
 · 
3 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Lab Criticized as ‘Slow to React’ in Bial’s Fatal Drug Trial
February 5, 2016
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
With Almost $200 Million in the Bank, WAVE Life Sciences Plans Six Clinical Programs in Three Years
January 29, 2016
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Akashi Halts DMD Clinical Trial, Third Company to Recently Have Problems With DMD Drug Trials
January 26, 2016
 · 
3 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Questions Remain as to What Caused the Bial Trial Tragedy in France
January 19, 2016
 · 
2 min read
Pfizer and Allergan Execs Emphasize Joint Company’s Pipeline, Hint Job Cuts Will Be Minimal
Drug Development
Biogen’s Promising Pipeline Underscores CEO’s High-Risk Strategy
January 18, 2016
 · 
4 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Drugmaker Unnamed as Botched Trial in France Leaves One Patient Brain Dead and Five Hospitalized
January 15, 2016
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Business
Booming Moderna Eyes Six Human Trials in 2016, Inks Deals with AstraZeneca PLC, Merck & Co. and Signed Huge Lease in Cambridge for R&D Growth
January 12, 2016
 · 
3 min read
Load More
PRESS RELEASES
Press Releases
/C O R R E C T I O N -- Skyhawk Therapeutics/
May 18, 2026
 · 
2 min read
Press Releases
Dragonfly Therapeutics Announces Encouraging Early Results from the Phase 1 for DF5112, its CCR6-Targeting Molecule
May 18, 2026
 · 
1 min read
Press Releases
Vast Therapeutics Presents Late-Breaking Phase 1 Data for Inhaled Therapy ALX1 at ATS 2026
May 18, 2026
 · 
2 min read
Press Releases
Bambusa Therapeutics Presents Positive Preliminary Phase 1 BBT002 Data at American Thoracic Society 2026 (ATS 2026) International Conference and Announces First Patient Dosed in Phase 1b/2a CRSwNP Trial
May 18, 2026
 · 
6 min read
Press Releases
Triveni Bio Doses First Healthy Volunteers with Next-Generation Bispecific Antibody TRIV-573 Targeting Kallikreins 5 & 7 and Interleukin 13 in Phase 1 Clinical Trial
May 18, 2026
 · 
3 min read
Press Releases
Earendil Labs Announces First Cohort Dosed in Phase I Study of Novel Biparatopic Antibody Targeting Thymic Stromal Lymphopoietin (TSLP)
May 18, 2026
 · 
2 min read
Press Releases
SEED Therapeutics to Present Phase 1 Trial Design for ST-01156, a First-in-Human Oral RBM39 Molecular Glue Degrader, at 2026 ASCO Annual Meeting
May 18, 2026
 · 
3 min read
Press Releases
Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia
May 18, 2026
 · 
8 min read
Press Releases
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202
May 18, 2026
 · 
4 min read
Press Releases
Prokarium Reports Positive Interim Data from Phase 1/1b PARADIGM-1 trial of ZH9 in NMIBC patients, Demonstrating Excellent Safety and Encouraging Early Efficacy
May 18, 2026
 · 
2 min read
Press Releases
Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich’s Ataxia on Monday, May 18, 2026
May 17, 2026
 · 
1 min read
Press Releases
Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer
May 17, 2026
 · 
9 min read
Press Releases
Atisama Therapeutics Advances RB042 into Multiple Ascending Dose cohorts of Phase 1 Trial and Appoints Bernard Coulie as Chair of the Board
May 17, 2026
 · 
4 min read
Press Releases
Positive Interim Data from Cohorts 1 and 2 of Tenaya’s RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adults with PKP2-associated ARVC
May 15, 2026
 · 
13 min read
Press Releases
SN BioScience Doses First Patient in Phase 1b/2 Clinical Trial of ‘SNB-101'
May 14, 2026
 · 
2 min read
Press Releases
Nurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg (NX-5948) in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual Meeting
May 14, 2026
 · 
7 min read
Press Releases
Imviva Biotech Presents Data Demonstrating Durable Clinical Responses from Ongoing Phase 1/2 Study of CTA313 in Systemic Lupus Erythematosus at ASGCT 2026
May 14, 2026
 · 
3 min read
Press Releases
Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program
May 14, 2026
 · 
11 min read
Press Releases
MIRA Pharmaceuticals Reports Positive Unblinded Phase 1 Data for Ketamir-2
May 14, 2026
 · 
6 min read
Press Releases
Forward Therapeutics Announces Completion of Phase 1 Trials with Two Internally Discovered Next-Generation TNF Signaling Inhibitors Supporting Advancement to Phase 2 Clinical Development
May 14, 2026
 · 
3 min read
Load More